Ye Xiaojuan, Sun Da, Lou Cen
Department of Nuclear Medicine, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China.
Department of Nuclear Medicine, Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310016, China.
J Cancer Res Ther. 2018;14(Supplement):S36-S40. doi: 10.4103/0973-1482.181172.
The aim of this study was to comparatively evaluate the efficacy of strontium-89 chloride ( SrCl) in treating bone metastasis-associated pain in patients with lung, breast, or prostate cancer.
The 126 patients with lung cancer included 88, 16, 15, 4, and 3 patients with adenocarcinoma, squamous cell carcinoma, nonsmall cell carcinoma, mixed carcinoma, and small cell carcinoma, respectively, and the control group consisted of patients with breast (71 patients) or prostate cancer (49 patients) who underwent SrCl treatment during the same period. The treatment dose of SrCl was 2.22 MBq/kg.
The efficacy rate of treatment in the lung cancer group was 75.4%, compared to 95.0% in the control group. Approximately 67% of patients with lung cancer and bone metastases and 47% of control patients exhibited mild-to-moderate reductions of leukocyte and platelet counts 4 weeks after SrCl treatment.
SrCl can safely and effectively relieve bone pain caused by bone metastasis from lung cancer. However, its efficacy was lower in patients with lung cancer with bone metastasis than in those with breast or prostate cancer with bone metastasis, and its effects on the peripheral hemogram were also significantly stronger in the lung cancer group.
本研究旨在比较评估氯化锶-89（SrCl）治疗肺癌、乳腺癌或前列腺癌患者骨转移相关疼痛的疗效。
126例肺癌患者中，腺癌、鳞状细胞癌、非小细胞癌、混合癌和小细胞癌患者分别为88例、16例、15例、4例和3例，对照组由同期接受SrCl治疗的乳腺癌患者（71例）或前列腺癌患者（49例）组成。SrCl的治疗剂量为2.22MBq/kg。
肺癌组的治疗有效率为75.4%，而对照组为95.0%。约67%的肺癌骨转移患者和47%的对照组患者在SrCl治疗4周后白细胞和血小板计数出现轻度至中度下降。
SrCl可安全有效地缓解肺癌骨转移引起的骨痛。然而，其对肺癌骨转移患者的疗效低于乳腺癌或前列腺癌骨转移患者，且其对肺癌组外周血常规的影响也明显更强。
